摘要
目的探究上皮性卵巢肿瘤血清中RASSF1A基因异常甲基化检测与临床意义。方法选择2014年2月—2016年2月于该院接受治疗的88例卵巢肿瘤患者,其中上皮性卵巢癌44例为观察组,良性肿瘤患者44例为对照组,再检测对比两组RASSF1A基因异常甲基化。结果观察组血清RASSF1A基因异常甲基化比率为56.8%显著高于对照组,差异有统计学意义,P<0.05;WHO病理II级、III级患者血清中RASSF1A基因异常甲基化比率为60.0%、81.8%均显著高于I级患者,差异有统计学意义,P<0.05;FIGO分级III^IV级患者血清中RASSF1A基因异常甲基化比率为80.0%显著高于I^II级患者,差异有统计学意义,P<0.05。结论在临床上诊断上皮性卵巢肿瘤可对RASSF1A基因异常甲基化进行检测,可为临床治疗与预后提供新思路,具有重要临床参考价值。
Objective To explore the RASSF1 A gene in epithelial ovarian cancer serum abnormal methylation detection and clinical significance. Methods From February 2014 to February 2016 in our hospital treated 88 cases of patients with ovarian tumors, including epithelial ovarian cancer in 44 cases of observation group, and 44 patients with benign tumor as the control group, to detect abnormal compared two groups of RASSF1 A gene methylation. Results Observation group serum abnormal methylation rate of RASSF1 A gene is 56.8% higher than that of control group, with statistical difference, P < 0.05; WHO pathological class II, III grade patients serum abnormal methylation rate of RASSF1 A gene is 60.0%, 81.8% were significantly higher than that of patients with grade I, statistically difference,P < 0.05; FIGO class III ~ IV in serum in patients with abnormal methylation rate of RASSF1 A gene is 80.0% higher than that of grade I ~ II patients, statistically difference,P < 0.05. Conclusion In clinical diagnosis of epithelial ovarian tumor of RASSF1 A gene abnormal methylation detection, can provide new ideas for clinical treatment and prognosis, has the important clinical reference value.
出处
《系统医学》
2016年第8期7-9,共3页
Systems Medicine
